ArticleScientific reports2024

Interleukin-17A is a potential therapeutic target predicted by proteomics for systemic sclerosis patients at high risk of pulmonary arterial hypertension.

Yuuichi Ono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.